Direct-to-Patient Survey Results Summary
Health Care, Innovation, Supply Chain
During the 2022 GCSG US conference in San Antonio, 65 attendees participated in our Direct-to-Patient (DtP) survey. While 2/3rd’s of the respondents represented pharmaceutical companies / sponsors, there is also a strong mix of input from service providers. Over 50% of participants also had experience with DtP. Though a need for technology improvements was noted, our industry’s adoption of patient centric services like DTP continues to boost the growth of decentralized trials.
Related Education Resources.
All ResourcesNat'l Coronavirus Response - Road Map to Reopening
Topics: Health Care, Strategic Planning
Report
Free
Lessons Learned: Conducting COVID Clinical Trials and Building a Clinical Supplies Team During the Peak of the Pandemic
Topics: Conference, COVID-19
Executive Summary
Members
Countdown to Brexit: Can your clinical supply chain pass the Brexit pressure test
Topics: Pharma Industry, Politics
White Paper
Members
